Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Aging Phys Act ; 29(3): 361-371, 2021 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-33373977

RESUMO

AIM: To compare the acute effects of two resistance exercise sessions with different partial blood flow restrictions (BFR) on hemodynamic parameters and cardiac autonomic modulation in older women with metabolic syndrome. METHODS: Thirty-nine older women (64.4 ± 4.5 years) were allocated into three groups: BFR0 = resistance exercise (20%, 1 maximum repetition [MR]) + 0% BFR; BFR60 = 20% 1 MR resistance exercise + 60% BFR; and BFR80 = 20% 1MR resistance exercise + 80% BFR. RESULTS: A reduction of 14 mmHg (BFR60 group) and 13 mmHg (BRF80 group) was observed 48 hr after the first exercise session, while vagal modulation was increased in the BRF60 group after 24 and 48 hr. CONCLUSION: A low-intensity resistance exercise session with 60% and 80% of BFR resulted in blood pressure (systolic, diastolic, and mean) reduction and positive changes on heart rate variability after 24 h of a RE session.


Assuntos
Treinamento Resistido , Idoso , Pressão Sanguínea , Feminino , Hemodinâmica , Humanos , Músculo Esquelético , Projetos Piloto , Fluxo Sanguíneo Regional
2.
Curr Cardiol Rev ; 16(3): 231-240, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31797762

RESUMO

BACKGROUND: Pulmonary Arterial Hypertension (PAH) is a severe and progressive disease of pulmonary arterioles. This pathology is characterized by elevation of the pulmonary vascular resistance and pulmonary arterial pressure, leading to right heart failure and death. Studies have demonstrated that resveratrol possesses a protective effect on the mechanisms related to the genesis of the PAH-induced by different models. OBJECTIVE: This study aimed to investigate the dose-related effects of resveratrol in different models of pulmonary arterial hypertension. METHODS: To identify eligible papers, we performed a systematic literature search on Scielo, Pub- Med, and Scholar Google. The research was limited to articles written in English in the last 10 years. We used the following descriptors to search: Pulmonary Arterial Hypertension and Resveratrol, OR Resveratrol, and Animal models of Pulmonary Arterial Hypertension, OR Resveratrol, and in vitro models of Pulmonary Arterial Hypertension. RESULTS: 1724 studies were identified through the descriptors used, fifty-five studies with different models of pulmonary arterial hypertension were selected for the full review, forty-four were excluded after application of exclusion and inclusion criteria, totalizing eleven studies included in this systematic review. CONCLUSION: The results showed that resveratrol, at low and high doses, protects in a dosedependent manner against the development of PAH induced through monocrotaline, normoxia and hypoxia models. In addition to having chemopreventive, anti-inflammatory, antioxidant and antiproliferative properties. In the case of PAH-related myocardial injury, resveratrol protects cells from apoptosis, thus working as an antiapoptotic agent.


Assuntos
Antioxidantes/uso terapêutico , Hipertensão Arterial Pulmonar/tratamento farmacológico , Resveratrol/uso terapêutico , Animais , Antioxidantes/farmacologia , Modelos Animais de Doenças , Humanos , Masculino , Camundongos , Resveratrol/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...